ERBB2 and breast carcinoma: In the last 5 years, introduction of anti-HER2 therapies such as pertuzumab, T-DM1 or neratinib has improved survival outcomes in early-stage HER2-positive breast cancer beyond trastuzumab and chemotherapy.1